Abstract
Background
Studies of the GLP-1 receptor (GLP-1 R) have been directed at identifying polymorphisms in the GLP-1 R gene that may be a contributing factor in the pathogenesis of obesity and cardiovascular risk factors. Nevertheless, the role of GLP-1 R variants on body weight response after dietary intervention has not been evaluated.
Objective
We decided to analyze the effects of the rs6923761 GLP-1 R polymorphism on body weight changes and metabolic parameters after 3 months of a hypocaloric diet.
Design
A sample of 91 obese subjects was analyzed in a prospective way. The hypocaloric diet had 1,520 calories per day; 52 % of carbohydrates, 25 % of lipids and 23 % of proteins. Distribution of fats was: 50.7 % of monounsaturated fats, 38.5 % of saturated fats and 11.8 % of polyunsaturated fats.
Results
In both genotype groups (GG vs. GA + AA), weight, body mass index, fat mass, waist circumference, systolic blood pressure, total cholesterol, LDL cholesterol, leptin, insulin and HOMA levels decreased. No statistical differences were detected in these changes between genotypes. In wild group (GG genotype) (pretreatment and posttreatment), BMI, weight, fat mass, waist circumference and triglyceride levels were higher than (GA + AA) group.
Conclusion
Our data showed better anthropometric parameters and triglyceride levels in obese subjects with the mutant allele (A) of rs6923761 GLP-1R polymorphism. A lack of association of this polymorphism with weight loss or biochemical changes after a hypocaloric diet was observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BMI:
-
Body mass index
- GLP-1:
-
Glucagon-like peptide 1
- GLP-1-R :
-
Glucagon-like peptide 1 receptor
- HOMA:
-
Homeostasis model assessment
- CRP:
-
C reactive protein
References
Kieffer TJ, Habener JF (1999) The glucagon-like peptides. Endocr Rev 20:876–913
Holst JJ (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes/Metab Res Rev 18:430–441
Bullock BP, Heller RS, Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968–2978
Thorens B (1992) Expression cloning of the pancreatic β-cell receptor for the gluco-incretin hormone glucagon peptide-1. Proc Natl Acad Sci USA 89:8641–8645
Tokuyama Y, Matsui K, Egashira T, Nozaki O, Ishizuka T, Kanatsuka A (2004) Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res Clin Pract 66:63–69
Beinborn M, Worrall CI, McBride MW, Kopin AS (2005) A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept 130:1–6
Sathananthan A, Dalla C, Micheletto F, ZInsmeister A, Camilleri M, Giesler P (2010) Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects. Diabetes Care 33:2074–2076
Kumada M, Kihara S, Sumitsuji S (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89
Shimomoura I, Hammer RE, Ikemoto S (1999) Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73–76
Steppan CM, Bailey ST, Bhat S (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312
Matsuzawa Y (2005) Adipocytokines: emerging therapeutic targets. Curr Atheroscler Rep 7:58–62
Mataix J, Mañas M (2003) Tablas de composición de alimentos españoles. University of Granada, Granada
Duart MJ, Arroyo CO, Moreno JL (2002) Validation of a insulin model for the reactions in RIA. Clin Chem Lab Med 40:1161–1167
Mathews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–414
Pfutzner A, Langefeld M, Kunt T et al (2003) Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin lab 49:571–576
Meier U, Gressner M (2004) Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, Ghrelin, adiponectin, and resistin. Clin Chem 50:1511–1525
Suominen P (2004) Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clin Chem 50:219–221
Lubrano V, Cocci F, Battaglia D et al (2005) Usefulness of high-sensitivity IL6 measurement for clinical characterization of patients with coronary artery disease. J Clin Lab Anal 19:110–114
Fortin JP, Schroeder J, Zhu Y, Beinborn M, Kopin A (2010) Pharmacological characterization of human incretin receptor missense variants. J Pharmacol Exp Ther 332:274–280
Sheikh H, Dougherty L, Hayden E, Klein D (2010) GLP-1 R gene polymorphism Leu260Phe is associated with morning cortisol in preschoolers. Prog Neuro Biol Psyc 34:980–983
Scrocchi LA, Marshall BA, Cook SM, Brubaker DJ (1998) Identification of GLP-1 actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47:632–639
Barash A, de grado T, Cano O, Bordiu E. Effect of GLP-1 receptor variants on weight loss and comorbidities in obese patients under bariatric surgery. 54 Congress of Endocrinology Society Madrid 2012. Abstract
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Luis, D.A., Aller, R., Izaola, O. et al. Effect of rs6923761 gene variant of glucagon-like peptide 1 receptor on metabolic response and weight loss after a 3-month intervention with a hypocaloric diet. J Endocrinol Invest 37, 935–939 (2014). https://doi.org/10.1007/s40618-014-0117-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-014-0117-2